https://quantumventureadvisors.com/2013/07/22/a-simple-vc-investment-model-what-every-biotech-entrepreneur-should-know/https://quantumventureadvisors.com/wp-content/uploads/2013/07/ownership3.pngOwnership StructureOwnership Structurehttps://quantumventureadvisors.com/wp-content/uploads/2013/07/exit-scenario.pngExit ScenarioExit Scenariohttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ownership2.pngOwnership Structurehttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ownership1.pngOwnership Structure (post-Series C)Ownership Structure (post-Series C)https://quantumventureadvisors.com/wp-content/uploads/2013/07/ownership.pngOwnership Structurehttps://quantumventureadvisors.com/wp-content/uploads/2013/07/complete-series.pngTable2: Series A - CTable2: Series A - Chttps://quantumventureadvisors.com/wp-content/uploads/2013/07/series-a.pngSeries A FinancingSeries A Financing2026-03-29T23:06:31+00:00monthlyhttps://quantumventureadvisors.com/2016/10/11/a-simple-vc-investment-model-what-every-biotech-entrepreneur-should-know-revised/https://quantumventureadvisors.com/wp-content/uploads/2016/10/ma-exit-scenario21.pngma-exit-scenario2https://quantumventureadvisors.com/wp-content/uploads/2016/10/ma-exit-scenario2.pngma-exit-scenario2https://quantumventureadvisors.com/wp-content/uploads/2016/10/ma-exit-scenario1.pngma-exit-scenario1https://quantumventureadvisors.com/wp-content/uploads/2016/10/ownership-structure2.pngownership-structurehttps://quantumventureadvisors.com/wp-content/uploads/2016/10/ownership-structure1.pngownership-structurehttps://quantumventureadvisors.com/wp-content/uploads/2016/10/ma-exit-scenario.pnghttps://quantumventureadvisors.com/wp-content/uploads/2016/10/ownership-structure.pngownership-structurehttps://quantumventureadvisors.com/wp-content/uploads/2016/10/model-assumptions.pngTable 1: Model AssumptionsTable 1: Model Assumptions2026-03-29T23:05:30+00:00monthlyhttps://quantumventureadvisors.com/2024/08/01/why-early-stage-tech-start-ups-fail/2024-08-01T10:03:12+00:00monthlyhttps://quantumventureadvisors.com/2023/10/13/generative-ai-and-creative-destruction/https://quantumventureadvisors.com/wp-content/uploads/2026/01/1648c-image-1.pngimage-1https://quantumventureadvisors.com/wp-content/uploads/2026/01/7b79d-image.pngimage2023-10-13T09:14:25+00:00monthlyhttps://quantumventureadvisors.com/2023/09/09/why-do-vc-funds-need-substantial-ownership-in-seed-rounds/https://quantumventureadvisors.com/wp-content/uploads/2023/09/pexels-photo-1072824.jpegperson holding a green plantPhoto by Akil Mazumder on <a href="https://www.pexels.com/photo/person-holding-a-green-plant-1072824/" rel="nofollow">Pexels.com</a>2023-09-09T07:22:51+00:00monthlyhttps://quantumventureadvisors.com/2023/08/26/why-a-deep-tech-strategy-makes-sense/https://quantumventureadvisors.com/wp-content/uploads/2023/08/image-1.pngimage-1https://quantumventureadvisors.com/wp-content/uploads/2023/08/image.pngimage2023-08-26T23:44:32+00:00monthlyhttps://quantumventureadvisors.com/2021/02/07/portfolio-management-and-covid-19-market-signals-biotech-and-the-sp-500/https://quantumventureadvisors.com/wp-content/uploads/2021/11/f3609-sp-excluding-crisis.pngSP-excluding-crisishttps://quantumventureadvisors.com/wp-content/uploads/2021/11/1e26e-portfolio.pngPortfoliohttps://quantumventureadvisors.com/wp-content/uploads/2021/11/cfbd8-screenshot-2021-02-07-at-4.48.28-pm.pngScreenshot-2021-02-07-at-4.48.28-PM2022-02-02T08:07:27+00:00monthlyhttps://quantumventureadvisors.com/2019/10/28/is-the-celgene-amgen-deal-for-otezla-fair/https://quantumventureadvisors.com/wp-content/uploads/2019/10/results-4.jpgResultshttps://quantumventureadvisors.com/wp-content/uploads/2019/10/tab-2.jpgTABhttps://quantumventureadvisors.com/wp-content/uploads/2019/10/tab-1.jpgTABhttps://quantumventureadvisors.com/wp-content/uploads/2019/10/scenario-2-2.jpghttps://quantumventureadvisors.com/wp-content/uploads/2019/10/scenario-1-2.jpghttps://quantumventureadvisors.com/wp-content/uploads/2019/10/results-3.jpgResultshttps://quantumventureadvisors.com/wp-content/uploads/2019/10/behcet-disease-2.jpghttps://quantumventureadvisors.com/wp-content/uploads/2019/10/tab.jpgTABhttps://quantumventureadvisors.com/wp-content/uploads/2019/10/scenario-2-1.jpgScenario 2https://quantumventureadvisors.com/wp-content/uploads/2019/10/scenario-1-1.jpg2022-02-02T08:05:19+00:00monthlyhttps://quantumventureadvisors.com/2019/08/19/biotech-rnpv-valuation-using-monte-carlo-simulation-a-simple-approach/https://quantumventureadvisors.com/wp-content/uploads/2019/08/monte-carlo-chart-1.jpgMonte Carlo Simulation charthttps://quantumventureadvisors.com/wp-content/uploads/2019/08/monte-carlo-chart.jpgMonte carlo simulation chartMonte carlo simulation chart2022-02-02T08:05:14+00:00monthlyhttps://quantumventureadvisors.com/2018/11/29/is-novartis-leading-the-way-in-pharma-rd-restructuring/https://quantumventureadvisors.com/wp-content/uploads/2018/11/novartis-1.jpgnovartishttps://quantumventureadvisors.com/wp-content/uploads/2018/11/novartis-e1576580399966.jpgnovartis2022-02-02T08:05:06+00:00monthlyhttps://quantumventureadvisors.com/2017/03/18/can-u-s-drug-prices-be-justified-a-u-s-vs-e-u-comparison/https://quantumventureadvisors.com/wp-content/uploads/2017/03/31.png3https://quantumventureadvisors.com/wp-content/uploads/2017/03/3.png3https://quantumventureadvisors.com/wp-content/uploads/2017/03/2.png2https://quantumventureadvisors.com/wp-content/uploads/2017/03/untitled.pngU.S. over EU5 Drug Pricing2022-02-02T08:05:00+00:00monthlyhttps://quantumventureadvisors.com/2017/03/04/a-simple-licensing-deal-model-for-your-biotech-start-up/https://quantumventureadvisors.com/wp-content/uploads/2017/03/licensing-1-e1576580242900.jpglicensinghttps://quantumventureadvisors.com/wp-content/uploads/2017/03/licensing.jpglicensing2022-02-02T08:04:54+00:00monthlyhttps://quantumventureadvisors.com/2016/12/07/modern-portfolio-theory-does-it-work-for-biotech/https://quantumventureadvisors.com/wp-content/uploads/2016/12/optimal1.pngoptimalhttps://quantumventureadvisors.com/wp-content/uploads/2016/12/optimal.pngoptimalhttps://quantumventureadvisors.com/wp-content/uploads/2016/12/final1.pngfinalhttps://quantumventureadvisors.com/wp-content/uploads/2016/12/final.pngfinalhttps://quantumventureadvisors.com/wp-content/uploads/2016/12/apple-tbill.pngapple-tbillhttps://quantumventureadvisors.com/wp-content/uploads/2016/12/risk-formulas2.pngrisk-formulashttps://quantumventureadvisors.com/wp-content/uploads/2016/12/return-formulas4.pngreturn-formulashttps://quantumventureadvisors.com/wp-content/uploads/2016/12/return-formulas3.pngreturn-formulashttps://quantumventureadvisors.com/wp-content/uploads/2016/12/risk-formulas1.pngrisk-formulashttps://quantumventureadvisors.com/wp-content/uploads/2016/12/return-formulas2.pngreturn-formulas2022-02-02T08:04:44+00:00monthlyhttps://quantumventureadvisors.com/2016/11/22/winners-and-losers-in-pharma-biotech-mergers-and-acquisitions-biogen-shines-again/https://quantumventureadvisors.com/wp-content/uploads/2016/11/ma-expenditure2.pngma-expenditurehttps://quantumventureadvisors.com/wp-content/uploads/2016/11/ma-effectiveness-ratio1.pngma-effectiveness-ratiohttps://quantumventureadvisors.com/wp-content/uploads/2016/11/ma-expenditure1.pngma-expenditurehttps://quantumventureadvisors.com/wp-content/uploads/2016/11/dcf-value1.pngdcf-valuehttps://quantumventureadvisors.com/wp-content/uploads/2016/11/ma-effectiveness-ratio.pngma-effectiveness-ratiohttps://quantumventureadvisors.com/wp-content/uploads/2016/11/ma-expenditure.pngma-expenditureFigure 2: Total, Time-Adjusted M&A Expenditure (As of 31/12/2015)https://quantumventureadvisors.com/wp-content/uploads/2016/11/dcf-value.pngdcf-value2022-02-02T08:04:33+00:00monthlyhttps://quantumventureadvisors.com/2016/11/06/brand-valuation-of-otc-pharmaceutical-businesses/https://quantumventureadvisors.com/wp-content/uploads/2016/11/wacc1.pngwacchttps://quantumventureadvisors.com/wp-content/uploads/2016/11/royalty-relief.pngroyalty-reliefhttps://quantumventureadvisors.com/wp-content/uploads/2016/11/weighted-value1.pngweighted-valuehttps://quantumventureadvisors.com/wp-content/uploads/2016/11/dcf1.pngdcfhttps://quantumventureadvisors.com/wp-content/uploads/2016/11/wacc.pngwacchttps://quantumventureadvisors.com/wp-content/uploads/2016/11/weighted-value.pngweighted-valuehttps://quantumventureadvisors.com/wp-content/uploads/2016/11/dcf.pngdcfhttps://quantumventureadvisors.com/wp-content/uploads/2016/11/consumer-care-val.pngconsumer-care-valhttps://quantumventureadvisors.com/wp-content/uploads/2016/11/bayer-ev-calculation.pngbayer-ev-calculationhttps://quantumventureadvisors.com/wp-content/uploads/2016/11/financials1.pngfinancials2022-02-02T08:04:19+00:00monthlyhttps://quantumventureadvisors.com/2016/08/03/sales-forecasting-in-the-pharmaceutical-industry/https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma44.pngSMA4https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma4.jpgSMA4https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma43.pngSMA4https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma42.pngSMA4https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma52.pngSMA5https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma51.pngSMA5https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma41.pngSMA4https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma6.pngSMA6https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma5.pngSMA5https://quantumventureadvisors.com/wp-content/uploads/2016/08/sma4.png2022-02-02T08:04:04+00:00monthlyhttps://quantumventureadvisors.com/2015/11/20/10-things-i-learned-from-shark-tank/https://quantumventureadvisors.com/wp-content/uploads/2015/11/shark-tank-logo.jpgshark-tank-logo2022-02-02T08:03:59+00:00monthlyhttps://quantumventureadvisors.com/2019/12/16/implantable-biolectronics-the-future-of-biomedicine/https://quantumventureadvisors.com/wp-content/uploads/2019/12/feature-image-2.jpgHuman brain scan in a neurology clinichttps://quantumventureadvisors.com/wp-content/uploads/2019/12/feature-image-1.jpgFeature imagehttps://quantumventureadvisors.com/wp-content/uploads/2019/12/feature-image.jpgFeature imagehttps://quantumventureadvisors.com/wp-content/uploads/2019/12/bioelectronics.jpgBioelectronics2022-02-02T08:02:11+00:00monthlyhttps://quantumventureadvisors.com/2019/12/30/the-mathematics-of-venture-capital-returns/https://quantumventureadvisors.com/wp-content/uploads/2019/12/definitions_7.jpgDefinitions_7https://quantumventureadvisors.com/wp-content/uploads/2019/12/definitions_6.jpgDefinitions_6https://quantumventureadvisors.com/wp-content/uploads/2019/12/definitions_5.jpgDefinitions_5https://quantumventureadvisors.com/wp-content/uploads/2019/12/definitions_1.jpgDefinitions_1https://quantumventureadvisors.com/wp-content/uploads/2019/12/definitions_2.jpgDefinitions_2https://quantumventureadvisors.com/wp-content/uploads/2019/12/definitions_4.jpgDefinitions_4https://quantumventureadvisors.com/wp-content/uploads/2019/12/definitions_3.jpgDefinitions_32022-02-02T08:00:25+00:00monthlyhttps://quantumventureadvisors.com/2021/02/15/how-to-address-challenges-in-biotech-start-up-recruitment/2022-02-02T07:57:57+00:00monthlyhttps://quantumventureadvisors.com/about-2/https://quantumventureadvisors.com/wp-content/uploads/2021/11/064fa-05.jpg052022-02-02T07:45:14+00:00weekly0.6https://quantumventureadvisors.com/2015/07/05/venture-financing-trends-in-biotech-a-decade-of-healthy-investment-returns/https://quantumventureadvisors.com/wp-content/uploads/2015/07/investment-by-phase.jpgInvestment by PhaseInvestment by Phasehttps://quantumventureadvisors.com/wp-content/uploads/2015/07/investment-by-therapeutic-area1.jpgFigure 4: Pipeline by Therapeutic Area at the time of InvestmentFigure 4: Pipeline by Therapeutic Area at the time of Investment https://quantumventureadvisors.com/wp-content/uploads/2015/07/investment-by-therapeutic-area.jpgInvestment by Therapeutic AreaInvestment by Therapeutic Areahttps://quantumventureadvisors.com/wp-content/uploads/2015/07/ipo-raise.jpgIPO RaiseIPO Raisehttps://quantumventureadvisors.com/wp-content/uploads/2015/05/ipo-raise1.pngFigure 2: Total Amount of IPO Raise by Year - Average IPO Raise per IPOFigure 2: Total Amount of IPO Raise by Year - Average IPO Raise per IPOhttps://quantumventureadvisors.com/wp-content/uploads/2015/05/ipo-raise.pngFigure 2: Total Amount of IPO Raise by Year - Average IPO Raisehttps://quantumventureadvisors.com/wp-content/uploads/2015/05/vc-investment-vc-average-deal-size.pngFigure 1: Total VC Investment Deal Value by Year - Average VC Investment per DealFigure 1: Total VC Investment Deal Value by Year - Average VC Investment per Dealhttps://quantumventureadvisors.com/wp-content/uploads/2015/05/vc-investment.pngFigure 1: VC Investment Deals Value by YearFigure 1: VC Investment Deals Value by Year2021-11-25T16:15:10+00:00monthlyhttps://quantumventureadvisors.com/2014/12/12/do-scientists-accept-management-processes/https://quantumventureadvisors.com/wp-content/uploads/2014/12/hands-on-desk-at-meeting.jpghands-on-desk-at-meeting2021-11-25T16:15:10+00:00monthlyhttps://quantumventureadvisors.com/2014/10/12/structuring-and-developing-an-effective-business-plan/https://quantumventureadvisors.com/wp-content/uploads/2014/10/steps-to-business-plan.jpgsteps-to-business-plan2021-11-25T16:15:10+00:00monthlyhttps://quantumventureadvisors.com/2014/07/02/a-primer-on-determining-the-appropriate-type-of-investor-for-your-company/https://quantumventureadvisors.com/wp-content/uploads/2014/07/type-of-investor.pngRelevant Investor by CompanyRelevant Investor by Companyhttps://quantumventureadvisors.com/wp-content/uploads/2014/07/company-financials.pngCompany FinancialsCompany Financials2021-11-25T16:15:10+00:00monthlyhttps://quantumventureadvisors.com/2013/11/13/viropharma-acquisition-by-shire-pharmaceuticals-was-the-price-right/https://quantumventureadvisors.com/wp-content/uploads/2013/11/screen-shot-2013-11-13-at-01-26-36.pngFigure 2: Implied Market Value of Equity of ViropharmaFigure 2: Implied Market Value of Equity of Viropharmahttps://quantumventureadvisors.com/wp-content/uploads/2013/11/screen-shot-2013-11-13-at-01-20-121.pngFigure 2: Implied Market Value of Equity of ViropharmaFigure 2: Implied Market Value of Equity of Viropharmahttps://quantumventureadvisors.com/wp-content/uploads/2013/11/screen-shot-2013-11-13-at-01-20-12.pngMarket Value of ViropharmaMarket Value of Viropharmahttps://quantumventureadvisors.com/wp-content/uploads/2013/11/viropharma-multiples.pngViropharma MultiplesViropharma Multiples2021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/2014/05/31/common-mistakes-in-valuation-discounted-cash-flow/https://quantumventureadvisors.com/wp-content/uploads/2014/05/fourth.pngCommon Financial Modelling MistakesCommon Financial Modelling Mistakeshttps://quantumventureadvisors.com/wp-content/uploads/2014/05/third.pngFree Cash Flow (Projected Period) CalculationFree Cash Flow (Projected Period) Calculationhttps://quantumventureadvisors.com/wp-content/uploads/2014/05/second.pngFree Cash Flow (Current & Previous Periods) CalculationFree Cash Flow (Current & Previous Periods) Calculationhttps://quantumventureadvisors.com/wp-content/uploads/2014/05/first.pngWACC CalculationWACC Calculation2021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/2014/04/24/pfizer-astrazeneca-ma-rumors-is-us-101-bn-the-right-price/https://quantumventureadvisors.com/wp-content/uploads/2014/04/figure-3.pngEstimation of AstraZeneca's Market Value of EquityEstimation of AstraZeneca's Market Value of Equityhttps://quantumventureadvisors.com/wp-content/uploads/2014/04/figure-2.pngWACC CalculationWACC Calculationhttps://quantumventureadvisors.com/wp-content/uploads/2014/04/figure-1.pngFree Cash Flow CalculationFree Cash Flow Calculation2021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/useful-links-2/2021-11-25T16:15:09+00:00weekly0.6https://quantumventureadvisors.com/2013/10/07/strategic-target-screening-in-ma-when-and-how/https://quantumventureadvisors.com/wp-content/uploads/2013/10/motives-criteria1.pngMotives & CriteriaMotives & Criteriahttps://quantumventureadvisors.com/wp-content/uploads/2013/10/motives-criteria.pngMotives & CriteriaMotives & Criteria2021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/2013/11/26/dcf-and-npv-methods-and-the-effect-of-initial-sales-and-sales-growth/https://quantumventureadvisors.com/wp-content/uploads/2013/11/sensitivity-analysis-1.pngSensitivity Analysis - Initial Sales and CAGR effect on NPVSensitivity Analysis - Initial Sales and CAGR effect on NPVhttps://quantumventureadvisors.com/wp-content/uploads/2013/11/npv-21.pngNPV of the ProjectNPV of the Projecthttps://quantumventureadvisors.com/wp-content/uploads/2013/11/npv-2.pngnhttps://quantumventureadvisors.com/wp-content/uploads/2013/11/dcf.pngDiscounted Cash Flow MethodologyDiscounted Cash Flow Methodologyhttps://quantumventureadvisors.com/wp-content/uploads/2013/11/discount-rate-by-phase.pngDiscount Rate by PhaseDiscount Rate by Phasehttps://quantumventureadvisors.com/wp-content/uploads/2013/11/rd-costs.pngR&D Costs by PhaseR&D Costs by Phasehttps://quantumventureadvisors.com/wp-content/uploads/2013/11/comparables.pngComparable CompaniesComparable Companies2021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/2013/12/31/vectura-plc/https://quantumventureadvisors.com/wp-content/uploads/2013/12/24.jpg242021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/2014/01/05/the-u-s-small-and-mid-cap-biotech-shines-stocks-on-the-rise/https://quantumventureadvisors.com/wp-content/uploads/2014/01/shiny-biotech-stocks1.pngShiny Biotech StocksShiny Biotech Stockshttps://quantumventureadvisors.com/wp-content/uploads/2014/01/shiny-biotech-stocks.pngBiotech Stocks on the Risehttps://quantumventureadvisors.com/wp-content/uploads/2014/01/screen-shot-2014-01-05-at-20-48-30.pngNASDAQ Biotechnology IndexNASDAQ Biotechnology Index2021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/2014/02/02/post-ipo-performance-of-u-s-biotechnology-companies/https://quantumventureadvisors.com/wp-content/uploads/2014/02/bn-tu662_2uee5_or_20170609133926.jpgBN-TU662_2Uee5_OR_20170609133926https://quantumventureadvisors.com/wp-content/uploads/2014/02/download.jpgdownload2021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/2014/02/15/how-to-challenge-your-companys-forecasts/https://quantumventureadvisors.com/wp-content/uploads/2014/02/0_yplxpgxxcfhf8x34.jpg0_YplXpgxXCFhf8x342021-11-25T16:15:09+00:00monthlyhttps://quantumventureadvisors.com/2013/06/17/valuation-of-pharmaceutical-and-biotechnology-companies-dcf-part-1/https://quantumventureadvisors.com/wp-content/uploads/2013/06/final-dcf.pngEnterprise Value Estimation - Discounted Cash Flow ApproachEnterprise Value Estimation - Discounted Cash Flow Approachhttps://quantumventureadvisors.com/wp-content/uploads/2013/06/dcf.pngMarket Value of Equity Estimation - DCF ApproachMarket Value of Equity Estimation - DCF Approachhttps://quantumventureadvisors.com/wp-content/uploads/2013/06/ev1.pngEnterprise Value Calculation - DCF FormulaEnterprise Value Calculation - DCF Formulahttps://quantumventureadvisors.com/wp-content/uploads/2013/06/ev.pngDCF - Enterprise Value FormulaDCF - Enterprise Value Formulahttps://quantumventureadvisors.com/wp-content/uploads/2013/06/fcff.pngFCFF FormulaFCFF Formulahttps://quantumventureadvisors.com/wp-content/uploads/2013/06/sanofi-final3.pngSensitivity AnalysisSensitivity Analysishttps://quantumventureadvisors.com/wp-content/uploads/2013/06/sanofi-final2.pngSensitivity AnalysisSensitivity Analysishttps://quantumventureadvisors.com/wp-content/uploads/2013/06/sanofi-final1.pngSanofi Sensitivity AnalysisSanofi Sensitivity Analysishttps://quantumventureadvisors.com/wp-content/uploads/2013/06/sanofi-final.pngSensitivity AnalysisSensitivity Analysishttps://quantumventureadvisors.com/wp-content/uploads/2013/06/sanofi-dcf.pngSanofi DCFSanofi DCF2021-11-25T16:15:08+00:00monthlyhttps://quantumventureadvisors.com/2013/07/08/valuation-of-pharmaceutical-and-biotechnology-companies-comparable-transactions-method-part-3/https://quantumventureadvisors.com/wp-content/uploads/2013/07/synthesis.pngValuation SynthesisValuation Synthesishttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct-valuation2.pngMarket Value of Equity Estimation - CT ApproachMarket Value of Equity Estimation - CT Approachhttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct-valuation1.pngMarket Value of Equity Estimation - CT ApproachMarket Value of Equity Estimation - CT Approachhttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct-valuation.pngMarket Value of Equity Estimation - CT ApproachMarket Value of Equity Estimation - CT Approachhttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct-multiples.pngComparable Transactions MultiplesComparable Transactions Multipleshttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct-sample.pngComparable Transactions SampleComparable Transactions Samplehttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct5.pngWeighted ValuationWeighted Valuationhttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct4.pngM&A and Valuation AnalysisM&A and Valuation Analysishttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct32.pngCT ValuationCT Valuationhttps://quantumventureadvisors.com/wp-content/uploads/2013/07/ct31.pngCT ValuationCT Valuation2021-11-25T16:15:08+00:00monthlyhttps://quantumventureadvisors.com/2013/06/25/valuation-of-pharmaceutical-and-biotechnology-companies-comparable-multiples-method-part-2/https://quantumventureadvisors.com/wp-content/uploads/2013/06/cmm-final.pngMarket Value of Equity Estimation - CMM Approachhttps://quantumventureadvisors.com/wp-content/uploads/2013/06/comparables.pngComparables Companies - Average MultiplesComparables Companies - Average Multipleshttps://quantumventureadvisors.com/wp-content/uploads/2013/06/comparison.pngCMM derived vs. Actual Market CapitalisationCMM derived vs. Actual Market Capitalisationhttps://quantumventureadvisors.com/wp-content/uploads/2013/06/scenario4.pngPre and Post-acquisition ScenariosPre and Post-acquisition Scenarioshttps://quantumventureadvisors.com/wp-content/uploads/2013/06/scenario3.pngScenariohttps://quantumventureadvisors.com/wp-content/uploads/2013/06/scenario2.pngScenariohttps://quantumventureadvisors.com/wp-content/uploads/2013/06/scenario1.pngPre and Post-acquisition ScenariosPre and Post-acquisition Scenarioshttps://quantumventureadvisors.com/wp-content/uploads/2013/06/untitled.pngPre and Post-acquisition ScenariosPre and Post-acquisition Scenarioshttps://quantumventureadvisors.com/wp-content/uploads/2013/06/scenario.pngPre- and post- acquisition scenariosPre- and post- acquisition scenarioshttps://quantumventureadvisors.com/wp-content/uploads/2013/06/sanofi-financials_21.pngSanofi Financials_22021-11-25T16:15:08+00:00monthlyhttps://quantumventureadvisors.com/2013/08/09/pharmaceutical-industry-profile-report/https://quantumventureadvisors.com/wp-content/uploads/2013/08/pharmaceutical-industry-overview-1-638-e1576581754990.jpgpharmaceutical-industry-overview-1-6382021-11-25T16:15:08+00:00monthlyhttps://quantumventureadvisors.com/2013/08/28/5-ways-to-boost-your-companys-stock-price/https://quantumventureadvisors.com/wp-content/uploads/2013/08/all.pngLevel of Risk and Return of Different Types of InvestmentsLevel of Risk and Return of Different Types of Investmentshttps://quantumventureadvisors.com/wp-content/uploads/2013/08/financial-performance.pngLiterature - Effect of M&A on Stock ReturnLiterature - Effect of M&A on Stock Returnhttps://quantumventureadvisors.com/wp-content/uploads/2013/08/organisational-structure.pngOrganisational RestructuringOrganisational Restructuringhttps://quantumventureadvisors.com/wp-content/uploads/2013/08/preferred-shares.pngHow Preferred Shares Characteristics May Affect ValueHow Preferred Shares Characteristics May Affect Valuehttps://quantumventureadvisors.com/wp-content/uploads/2013/08/pfizer-stock.pngPfizer Stock Price since Stock Repurchase Program AnnouncementPfizer Stock Price since Stock Repurchase Program Announcementhttps://quantumventureadvisors.com/wp-content/uploads/2013/08/jj-stock.pngJohnson & Johnson Stock Price since Stock Repurchase Program AnnouncementJohnson & Johnson Stock Price since Stock Repurchase Program Announcementhttps://quantumventureadvisors.com/wp-content/uploads/2013/08/biogen-stock.pngBiogen Stock Price since Stock Repurchase Program AnnouncementBiogen Stock Price since Stock Repurchase Program Announcementhttps://quantumventureadvisors.com/wp-content/uploads/2013/08/amgen-stock.pngAmgen Stock Price since Stock Repurchase Program AnnouncementAmgen Stock Price since Stock Repurchase Program Announcement2021-11-25T16:15:08+00:00monthlyhttps://quantumventureadvisors.com/research-publications/2021-11-25T16:15:07+00:00weekly0.6https://quantumventureadvisors.com/2013/05/01/pharmaceutical-rd/https://quantumventureadvisors.com/wp-content/uploads/2013/05/4-figure2-1-1.png4-Figure2-1https://quantumventureadvisors.com/wp-content/uploads/2013/05/4-figure2-1.png4-Figure2-1https://quantumventureadvisors.com/wp-content/uploads/2013/05/4-figure2-1.png4-Figure2-1https://quantumventureadvisors.com/wp-content/uploads/2013/04/final.pngMean pipeline to mean R&D (USD bn.) vs. Mean EBITDA margin (%)Mean pipeline to mean R&D (USD bn.) vs. Mean EBITDA margin (%)https://quantumventureadvisors.com/wp-content/uploads/2013/04/ebitda_pipeline-rd.pngEBITDA_pipeline-R&DMean pipeline to mean R&D vs. Mean EBITDA margin2021-11-25T16:15:07+00:00monthlyhttps://quantumventureadvisors.com/2013/03/04/regenerative-medicine/https://quantumventureadvisors.com/wp-content/uploads/2013/03/shutterstock_691682311-750x500-3.jpgshutterstock_691682311-750x500https://quantumventureadvisors.com/wp-content/uploads/2013/03/shutterstock_691682311-750x500-2.jpgshutterstock_691682311-750x500https://quantumventureadvisors.com/wp-content/uploads/2013/03/shutterstock_691682311-750x500-1.jpgshutterstock_691682311-750x5002021-11-25T16:15:07+00:00monthlyhttps://quantumventureadvisors.com/2013/02/10/oncology/https://quantumventureadvisors.com/wp-content/uploads/2013/02/cordenpharma-wordcloud-focused-on-oncology-with-hand-and-marker.jpgcordenpharma-wordcloud-focused-on-oncology-with-hand-and-markerhttps://quantumventureadvisors.com/wp-content/uploads/2013/02/oncology-market.pngOncology marketFigure 4: Major players in the Oncology markethttps://quantumventureadvisors.com/wp-content/uploads/2013/02/global-pharma-market.pngGlobal Pharma MarketFigure 3: Global Pharma Market (2007 - 2011)https://quantumventureadvisors.com/wp-content/uploads/2013/02/global-oncology-market.pngglobal oncology marketFigure 2: Global Oncology Market (2007 - 2011)https://quantumventureadvisors.com/wp-content/uploads/2013/02/screen-shot-2013-02-10-at-4-17-16-pm.pngScreen shot 2013-02-10 at 4.17.16 PMFigure 2https://quantumventureadvisors.com/wp-content/uploads/2013/02/screen-shot-2013-02-10-at-4-14-57-pm.pngScreen shot 2013-02-10 at 4.14.57 PMFigure 2:https://quantumventureadvisors.com/wp-content/uploads/2013/02/screen-shot-2013-02-10-at-2-11-30-pm.pngFigure 1https://quantumventureadvisors.com/wp-content/uploads/2013/02/screen-shot-2013-02-10-at-2-07-08-pm.pngScreen shot 2013-02-10 at 2.07.08 PM2021-11-25T16:15:07+00:00monthlyhttps://quantumventureadvisors.com/2013/02/10/mergers-pharmaceutical-biotechnology/https://quantumventureadvisors.com/wp-content/uploads/2013/02/digital_graph_trends_2.jpgDigital_graph_trends_22021-11-25T16:15:07+00:00monthlyhttps://quantumventureadvisors.com/2013/05/08/business-models-in-the-pharmaceutical-industry-the-case-of-novo-nordisk/https://quantumventureadvisors.com/wp-content/uploads/2013/05/novonordisk-1.jpgRB PLUS/PFS Velkendte aktier kan give falsk tryghed(ARKIV) Novo Nordisk i Bagsværd, den 1. februar 2017. Lad dig ikke forblænde af trygheden ved velkendte danske virksomheder. Det er vigtigt at sprede sin investering ud over det danske marked. ** Historierne er klausuleret til lørdag. Fakta følger. Artiklerne udsendes til PFS-kunder mandag. Historierne må publiceres bag paywall lørdag kl. 06.00. **. (Foto: Liselotte Sabroe/Ritzau Scanpix)https://quantumventureadvisors.com/wp-content/uploads/2013/05/novonordisk.jpgnovonordiskhttps://quantumventureadvisors.com/wp-content/uploads/2013/05/novo.pngNovo Nordisk FinancialsNovo Nordisk Financialshttps://quantumventureadvisors.com/wp-content/uploads/2013/05/model.pngBusiness Model of Novo NordiskBusiness Model of Novo Nordiskhttps://quantumventureadvisors.com/wp-content/uploads/2013/05/agreements.pngNovo Nordisk Strategic Partnerships / AlliancesNovo Nordisk Strategic Partnerships / Alliances2021-11-25T16:15:07+00:00monthlyhttps://quantumventureadvisors.com/about/2020-01-24T11:53:58+00:00weekly0.6https://quantumventureadvisors.com/finance/2017-04-03T15:23:13+00:00weekly0.6https://quantumventureadvisors.com/strategy/2017-04-03T15:23:12+00:00weekly0.6https://quantumventureadvisors.com/about/topics/2016-10-11T12:53:39+00:00weekly0.6https://quantumventureadvisors.comdaily1.02026-03-29T23:06:31+00:00